Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | N549S |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR2 N549S lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N549S demonstrates increased transforming activity compared to wild-type Fgfr2 in culture (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 N549S |
Transcript | NM_000141.5 |
gDNA | chr10:g.121498521T>C |
cDNA | c.1646A>G |
Protein | p.N549S |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001144915.2 | chr10:g.121488064T>C | c.1646A>G | p.N549S | RefSeq | GRCh38/hg38 |
NM_001144919.2 | chr10:g.121488067T>C | c.1646A>G | p.N549S | RefSeq | GRCh38/hg38 |
NM_023029.2 | chr10:g.121488064T>C | c.1646A>G | p.N549S | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121498521T>C | c.1646A>G | p.N549S | RefSeq | GRCh38/hg38 |
NM_023029.2 | chr10:g.121488064T>C | c.1646A>G | p.N549S | RefSeq | GRCh38/hg38 |
NM_001144919.1 | chr10:g.121488067T>C | c.1646A>G | p.N549S | RefSeq | GRCh38/hg38 |
NM_001144915.1 | chr10:g.121488064T>C | c.1646A>G | p.N549S | RefSeq | GRCh38/hg38 |
NM_000141.5 | chr10:g.121498521T>C | c.1646A>G | p.N549S | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 N549S | Advanced Solid Tumor | sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N549S were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 N549S | Advanced Solid Tumor | resistant | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N549S were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |
FGFR2 N549S | Advanced Solid Tumor | sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N549S were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 N549S | Advanced Solid Tumor | sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N549S were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 N549S | Advanced Solid Tumor | sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N549S were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 N549S | Advanced Solid Tumor | sensitive | E7090 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N549S were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |